

CORRECTION

## Correction: Development of a novel immunoproteasome digestion assay for synthetic long peptide vaccine design

Hiroshi Wada, Atsushi Shimizu, Toshihiro Osada, Yuki Tanaka, Satoshi Fukaya, Eiji Sasaki

There are typographical errors in the fourth and fifth sentences of the Abstract. "IFN- $\mu$ " should appear as "IFN- $\gamma$ ." The correct sentences are: However, to confirm whether a multivalent vaccine can induce an individual epitope-specific CTL, the only viable screening strategies currently available are interferon-gamma (IFN- $\gamma$  enzyme-linked immunospot (ELISPOT) assays using human peripheral blood mononuclear cells, or expensive human leukocyte antigen (HLA)-expressing mice. In this report, we evaluated the use of our developed murine-20S immunoproteasome (i20S) digestion assay and found that it could predict the results of IFN- $\gamma$  ELISPOT assays.

There is a typographical error in the Abbreviations. "IFN- $\mu\Lambda$ , interferon-gamma" should appear as "IFN- $\gamma$ , interferon-gamma."

## Reference

 Wada H, Shimizu A, Osada T, Tanaka Y, Fukaya S, Sasaki E (2018) Development of a novel immunoproteasome digestion assay for synthetic long peptide vaccine design. PLoS ONE 13(7): e0199249. https://doi.org/10.1371/journal.pone.0199249 PMID: 29969453





Citation: Wada H, Shimizu A, Osada T, Tanaka Y, Fukaya S, Sasaki E (2018) Correction:
Development of a novel immunoproteasome digestion assay for synthetic long peptide vaccine design. PLoS ONE 13(10): e0205567. https://doi.org/10.1371/journal.pone.0205567

Published: October 4, 2018

Copyright: © 2018 Wada et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.